"10.1371_journal.pone.0054504","plos one","2013-01-24T00:00:00Z","Anne C Bay-Jensen; Stephanie Wichuk; Inger Byrjalsen; Diana J Leeming; Nathalie Morency; Claus Christiansen; Morten A Karsdal; Walter P Maksymowych","Rheumatology, Nordic Bioscience, Herlev, Denmark; Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada","Conceived and designed the experiments: ACBJ SW MK WPM CC. Performed the experiments: ACBJ DJL SW NM. Analyzed the data: ACBJ SW MK WPM CC. Contributed reagents/materials/analysis tools: ACBJ SW IB DJL NM CC MK WPM. Wrote the paper: ACBJ SW MK WPM CC.","ACBJ, IB, DJL and MK are full time employees at, and CC and MK hold stocks in, Nordic Bioscience. This study was partly funded by Nordic Bioscience. Nordic Bioscience is a privately-owned; small-medium size enterprise partly focused the development of biomarkers for rheumatic and fibrotic diseases. The two biomarkers described in the manuscript are patented by Nordic Bioscience (C2M, ASSAY FOR A TYPE II COLLAGEN BIOMARKER Patent Application WO/2012/038331; C3M, FIBROSIS BIOMARKER ASSAY Patent Application WO/2010/115749 & United States Patent Application 20100209940). Further research on the markers will be conducted which may lead to commercialization. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. WP, SW and NM have no financial or competing interest to declare. WP is a Medical Scientist of the Alberta Heritage Foundation for Medical Research.","2013","01","Anne C Bay-Jensen","ACBJ",8,TRUE,5,4,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
